Canagliflozin (Invokana)
SGLT2 inhibitor · SGLT2 class · oral smd · Johnson & Johnson
Top dose
300 mg
HbA1c reduction
-0.93%
at week 26 · efficacy
AE discontinuation
5.0%
Status
approved
Pivotal trial
- Trial
- CANTATA (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 26 weeks
- ClinicalTrials.gov
- NCT01081834
- Sponsor
- Johnson & Johnson
Notes
Canagliflozin 300 mg has the deepest HbA1c effect in the SGLT2 class (~-0.9 to -1.0%). CANVAS / CREDENCE established cardio-renal benefit. The original blockbuster SGLT2, now off-patent.